Ishii Masao
Yokohama Seamen's Insurance Hospital.
Nihon Rinsho. 2004 Jan;62(1):193-202.
Clinical use of type 1 angiotensin II receptor blockers(ABRs) is rapidly increasing because of their high safety as well as excellent efficacy. Recent clinical trials have demonstrated that telmisartan at a daily dose of 20-80 mg, olmesartan medoxomil at 10-40 mg, and irbesartan at 150-300 mg are effective and safe for the treatment of essential hypertension, severe hypertension and hypertension associated with renal diseases. These ARBs are similar to ACE inhibitors in terms of antihypertensive efficacy, but lack the adverse effect of cough. Long-term effects should be compared among ARBs, ACE inhibitors, and other antihypertensive drugs.
1型血管紧张素II受体阻滞剂（ABRs）因其高安全性和卓越疗效，在临床中的应用正在迅速增加。最近的临床试验表明，每日剂量为20 - 80毫克的替米沙坦、10 - 40毫克的奥美沙坦酯和150 - 300毫克的厄贝沙坦，对于治疗原发性高血压、重度高血压以及与肾脏疾病相关的高血压有效且安全。这些ARB在降压疗效方面与ACE抑制剂相似，但没有咳嗽的不良反应。应比较ARB、ACE抑制剂和其他降压药物的长期效果。
